← board
SNSE
distress 0/10 · well-funded / low risk$25.96-28%today-28% from 52w high
Revenue
pre-revenue
Liquidity
$293M
Runway
12.2 yrs
Shares 1y
+6%
Price & events
+129.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-28.2%
1D
-28.2%
1W
+55.9%
1M
-14.9%
3M
+148.7%
6M
+223.7%
1Y
—
2Y
—
5Y
+152.0%
All
Overview
- Market Cap
- $34.84M
- Volume
- 98.56K
- 52 Week Range
- $6.80 – $36.17
- Total Shares
- 1.34M
- Float Shares
- 811.87K
- Short %
- 84.60%
- % Held by Insiders
- 28.29%
- % Held by Institutions
- 153.02%
- RVOL
- 1.07x
- Beta
- -0.23
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,341,941 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $52 (+99% upside) · 3 analysts
- 2026-06-22HC Wainwright & Co.Buy
- 2026-06-15BTIGBuy
- 2026-06-11BTIGBuy
- 2026-05-29Cantor FitzgeraldOverweight
- 2026-05-28LUCID CAPITAL MARKETSBuy
- 2026-05-22CitigroupBuy
Competitors
- none identified
Recent news
- 2026-06-27SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
- 2026-06-20Sensei Biotherapeutics Stock - background and long-term strategy - AD HOC NEWS
- 2026-06-18Sensei Biotherapeutics Inc (SNSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
- 2026-06-18Faeth Therapeutics (NASDAQ: SNSE) launches $150M at-the-market stock program - Stock Titan
- 2026-06-16Director at Sensei Biotherapeutics (NASDAQ: SNSE) awarded 25,000 stock options - Stock Titan
- 2026-06-16Director Ramasastry lists merger-based options in Sensei Biotherapeutics (SNSE) - Stock Titan
- 2026-06-16Director at Sensei Biotherapeutics (NASDAQ: SNSE) gains shares, options - Stock Titan
- 2026-06-16Sensei Biotherapeutics (NASDAQ: SNSE) CEO granted merger-related equity awards - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.